Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

37.5%

3 terminated/withdrawn out of 8 trials

Success Rate

62.5%

-24.0% vs industry average

Late-Stage Pipeline

38%

3 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3

3(37.5%)

Phase 1

3(37.5%)

Phase 2

2(25.0%)

8Total

Phase 3(3)

Phase 1(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT00823342Phase 3Terminated

ANRS HB 05 Multicenter Study Evaluating Efficacy and Safety of Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy of Clevudine and Tenofovir for 96 Weeks in HBeAg Negative Patients With Chronic Hepatitis B, naïve to Anti-VHB Therapy

Role: collaborator

NCT01359644Phase 2Completed

Study to Determine the Safety and Effectiveness of Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) in Patients Who Have Previously Not Received the Standard of Care

Role: collaborator

NCT00496002Phase 3Terminated

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus

Role: lead

NCT00382798Phase 1Completed

Adaptive Phase I HCV Study With Nucleoside Analogue, in Combination With Interferon and Ribavirin

Role: lead

NCT00496158Phase 3Terminated

Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus

Role: lead

NCT00121979Phase 2Completed

Study Comparing Racivir and Lamivudine in Treatment-Experienced HIV Subjects